PI
DAWN

PFS Investments’s Day One Biopharmaceuticals DAWN Stock Holding History

PFS Investments’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$137K Buy
+11,505
New +$150K ﹤0.01% 504

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

PFS Investments's DAWN Position: Q2 2023 in Review

PFS Investments opened a new position in Day One Biopharmaceuticals (DAWN) in Q2 2023: 11,505 shares worth $137K. The stake represents ﹤0.01% of the portfolio and ranks #504 among its holdings.

140 funds tracked by Wall St. Rank hold DAWN as of Q2 2023.

  • PFS Investments held 11,505 shares of Day One Biopharmaceuticals worth $137K as of Q2 2023.
  • Day One Biopharmaceuticals was a new PFS Investments position in Q2 2023.
  • Day One Biopharmaceuticals made up ﹤0.01% of PFS Investments's portfolio in Q2 2023, its #504 holding.
  • 140 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.